logo
Plus   Neg
Share
Email

Aviva Appoints Amanda Blanc To Succeed Maurice Tulloch As CEO, With Immediate Effect

Aviva plc (AV.L,AV) announced Monday the appointment of Amanda Blanc as Chief Executive Officer with immediate effect. She succeeds Maurice Tulloch, the previous Chief Executive, who has stepped down from the role and retired from his position on the Board citing family health reasons.

Blanc is currently an Independent Non-Executive Director at the company. She was appointed to the Aviva Board in January 2020 and chairs the Customer, Conduct and Reputation Board Committee.

Following her appointment, Blanc will step down from all of her current Non-Executive commitments. She will continue in her voluntary role as Chair of the Welsh Professional Rugby Board.

Previously, she was CEO, EMEA & Global Banking Partnerships at Zurich Insurance Group. Prior to that, she was Group CEO, AXA UK, PPP and Ireland and has served as Chair of the Association of British Insurers and President of the Chartered Insurance Institute.

Maurice joined Aviva in 1992, and joined the Aviva Board in 2017. He was appointed as Chief Executive in March 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk, chief executive of electric car maker Tesla, said its own battery cells, which are under development now, will not reach high-volume production until 2022. This delay can affect the Cybertruck, Semi, and Roadster programs. He also said the company intends to increase battery cell purchases from partners Panasonic, LG & CATL, and possibly other partners. U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test.
Follow RTT